3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
44
HER2-positive Breast Cancer
8
Carcinoma, Non-Small-Cell Lung
5
Breast Diseases
3
Brain Neoplasms
3
Advanced Breast Cancer
3
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Rare Tumor
1
Pathologic Complete Response
1
Non Small Cell Lung
1
Neoplasm Metastasis
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Metastatic Breast Cancer in the Brain
1
Lung Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2+ Early or Locally Advanced Breast Cancer
1
HER2 Positive Metastatic Breast Cancer
1
HER2 Positive Breast Cancer
1
HER2 Insertion Mutation Positive Advanced NSCLC
1
Estrogen Receptor-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Cancer Invasive
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
pyrotinib
×
Clear all
NCT04355858
2022-07-26
MULAN
Fudan University
Phase 2
Unknown
319 enrolled